Sensus Healthcare Inc (NASDAQ:SRTS) Sees Large Increase in Short Interest

Sensus Healthcare Inc (NASDAQ:SRTS) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 107,300 shares, a growth of 24.2% from the December 31st total of 86,400 shares. Based on an average trading volume of 28,200 shares, the short-interest ratio is currently 3.8 days. Currently, 0.9% of the shares of the stock are short sold.

Several brokerages have recently issued reports on SRTS. TheStreet cut Sensus Healthcare from a “c-” rating to a “d+” rating in a report on Friday, November 22nd. B. Riley cut Sensus Healthcare from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $14.00 to $5.50 in a report on Thursday, November 7th. ValuEngine raised Sensus Healthcare from a “hold” rating to a “buy” rating in a report on Friday, January 3rd. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Sensus Healthcare in a report on Thursday, November 7th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $7.88.

NASDAQ:SRTS traded down $0.01 during midday trading on Monday, hitting $4.22. 494 shares of the company traded hands, compared to its average volume of 27,759. The firm’s fifty day moving average is $3.77 and its 200-day moving average is $5.00. Sensus Healthcare has a 12-month low of $3.31 and a 12-month high of $9.23. The firm has a market capitalization of $69.63 million, a P/E ratio of -28.13 and a beta of -0.61. The company has a current ratio of 5.01, a quick ratio of 4.66 and a debt-to-equity ratio of 0.04.

Sensus Healthcare (NASDAQ:SRTS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. Sensus Healthcare had a negative return on equity of 9.78% and a negative net margin of 9.83%. The company had revenue of $5.84 million for the quarter, compared to analyst estimates of $7.77 million. On average, research analysts expect that Sensus Healthcare will post -0.16 EPS for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. increased its stake in Sensus Healthcare by 40.7% in the second quarter. BlackRock Inc. now owns 103,643 shares of the company’s stock worth $574,000 after purchasing an additional 29,990 shares during the period. Essex Investment Management Co. LLC bought a new position in shares of Sensus Healthcare during the 3rd quarter worth $540,000. Susquehanna International Group LLP grew its position in shares of Sensus Healthcare by 69.9% during the 2nd quarter. Susquehanna International Group LLP now owns 27,492 shares of the company’s stock worth $152,000 after buying an additional 11,311 shares in the last quarter. Finally, Wells Fargo & Company MN bought a new position in shares of Sensus Healthcare during the 2nd quarter worth $30,000. Institutional investors and hedge funds own 9.43% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Further Reading: Sell-Side Analysts

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.